2015 Annual Meeting: Skin Diseases On Demand

You can earn up to 10.25 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 3.5 MOC Part II Self-Assessment credits. Cost: $205 $99 for College Members, $305 $150 for non-members.

This package of courses includes the following skin disease related sessions from the 2015 ACAAI Annual Meeting in San Antonio:

  • Controversial Manifestations of Contact Dermatitis
  • Triumvirate of Parameters for Allergic Skin Diseases
  • Hereditary Angioedema: Management Challenges
  • W11 Atopic Dermatitis In-Depth
  • W19 Living With an Itch: A Practical Approach to Diagnosis and Treatment

Release Date: 12/15/2015
Expiration Date: 12/14/2018


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 10.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

• Discuss the relationship between metal hypersensitivity and prosthetic joint failure
• Discuss similarities and differences in allergic reactions to cardiovascular, dental and gynecologic medical devices
• Identify other causes of dermatitis with generalized distribution such  as systemic contact dermatitis to drug, food and fragrances

• Describe important identifiable causes of chronic urticaria that warrant further diagnostic work-up and discuss evidence basis for, and appropriate uses of, anti-IgE therapy for idiopathic chronic urticaria
• Discuss Practice Parameter summary statements regarding the management of refractory atopic dermatitis
• Describe proper use of patch testing and implications for management

• Recognize the clinical presentations of HAE and how to distinguish it from histamine mediated angioedema
• Appropriately determine in whom to prescribe phophylactic HAE therapy 
• Discuss the risks, benefits, and costs of available HAE treatments

• Identify common and uncommon causes of severe eczema and describe the rationale for an extended therapeutic ladder for patients refractory to standard treatments with special emphasis on compliance

• Discuss the causes of pruritus, with (including atopic dermatitis) or without a rash and the workup to seek underlying diseases; and recognize that pruritus has numerous pathways and available therapies to address itch in patients with both idiopathic pruritus and pruritus secondary to another disease 

Additional information

Luz S. Fonacier, MD, FACAAI -- Speaker: Baxter; Supported/Contracted Research: Baxter, Genentech, Merck

Stephen A. Tilles, MD, FACAAI -- Supported/Contracted Research: Amgen, Astellas, AstraZeneca, Biota, Circassia, DBV Technologies, Genentech, Merck, Mylan, Novartis, Perrigo, Teva

David M. Lang, MD, FACAAI -- Consultant/Advisor: Genentech, GlaxoSmithKline, Meda, Merck; Speaker: Genentech; Supported/Contracted Research: Genentech, Merck 

Mark Boguniewicz, MD, FACAAI -- Consultant/Advisor: Celgene, Regeneron; Supported/Contracted Research: Anacor

Luz S. Fonacier, MD, FACAAI -- Speaker: Baxter; Supported/Contracted Research: Baxter, Genentech, Merck

Richard G. Gower, MD, FACAAI -- Consultant/Advisor: CSL Behring, Dyax, HollisterStier, Mylan, Shire, Teva; Speaker: CSL Behring, Mylan, Shire, Teva; Supported/Contracted Research: Anacor, Biocryst, Circassia, CSL Behring, Dyax, Genentech, GlaxoSmithKline, Kedrion, Mylan, Optinose, Pearl, Regeneron, Shire, Teva; Stock: Merck 

Marc A. Riedl, MD, MS -- Consultant/Advisor: Baxter, BioCryst, CSL Behring, Dyax, Salix, Shire: Speaker: Baxter, CSL Behring, Dyax, Salix, Shire: Supported/Contracted Research: Amgen, Biocryst, CSL Behring, Dyax, Shire 

Bruce L. Zuraw, MD, FACAAI -- Consultant/Advisor: BioCryst, CSL Behring, Dyax, Genentech, Isis, Novartis, Sanofi, Shire

Peter A. Lio, MD -- Consultant/Advisor: Anacor, Galderma, Johnson & Johnson, Pierre Fabre, Valeant 

The following have no financial relationships to disclose:

Peter Schalock, MD

James S. Taylor, MD, FACAAI

David E. Cohen, MD

Course summary
Available credit: 
  • 10.25 AMA PRA Category 1 Credit™
  • 10.25 Attendance
  • 3.50 MOC
Course opens: 
Course expires: 

Available Credit

  • 10.25 AMA PRA Category 1 Credit™
  • 10.25 Attendance
  • 3.50 MOC

Accreditation Period

Course opens: 
Course expires: 


Please login or create an account to take this course.